Literature DB >> 15622489

Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.

Yoko Yoshioka1, Etsuko Hashimoto, Satoru Yatsuji, Hiroyuki Kaneda, Makiko Taniai, Katsutoshi Tokushige, Keiko Shiratori.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a liver disease characterized by the histological features of steatohepatitis in the absence of significant alcohol consumption. The natural history of NASH is poorly defined. Here we report our experience with a patient to illustrate the clinical course of cirrhotic NASH. A 67-year-old woman was admitted with hematemesis due to the rupture of esophageal varices. Her varices were treated by endoscopic ligation and endoscopic sclerotherapy. Her medical history was unremarkable. Both the patient and her family members were asked about alcohol intake several times during her illness, but all of them denied a history of alcohol intake. She had insulin resistance, as determined by homeostasis model assessment. Serological tests for viral hepatitis were all negative. Viral hepatitis, autoimmune liver disease, iron overload, and metabolic liver disorders were all excluded. Imaging tests failed to reveal any steatosis, because of the presence of severe fibrosis. Liver biopsy showed moderate steatosis, moderate inflammation, ballooning degeneration, and Mallory bodies. We diagnosed NASH associated with cirrhosis based on the clinicopathological features. Almost 2 years later, she developed hepatocellular carcinoma (HCC) and she died of multiple HCCs. At autopsy, tumor invasion was seen throughout liver segment 8. The noncancerous liver showed burnt-out NASH; the steatosis, necroinflammation, ballooning degeneration, and Mallory bodies had all disappeared. In Japan, the prevalence of nonalcoholic fatty liver disease will increase as obesity has been increasing, so it is important to understand how to diagnose NASH. When a patient has NASH, careful follow-up should be performed.

Entities:  

Mesh:

Year:  2004        PMID: 15622489     DOI: 10.1007/s00535-004-1475-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

1.  Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Mitsuhito Koizumi; Shinya Furukawa; Teruhisa Ueda; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

Review 2.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

3.  Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?

Authors:  Satoru Yatsuji; Etsuko Hashimoto; Hiroyuki Kaneda; Makiko Taniai; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

Review 4.  Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.

Authors:  Yeo-Jung Kwon; Sangyun Shin; Young-Jin Chun
Journal:  Arch Pharm Res       Date:  2021-01-23       Impact factor: 4.946

5.  Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians.

Authors:  Kaushal Madan; Yogesh Batra; S Datta Gupta; Bal Chander; K D Anand Rajan; M S Tewatia; S K Panda; S K Acharya
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Varun Chandrashekaran; Firas Al Hasson; Udai P Singh; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Eur J Pharmacol       Date:  2018-09-05       Impact factor: 4.432

7.  Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.

Authors:  Katsutoshi Tokushige; Etsuko Hashimoto; Yoshinori Horie; Makiko Taniai; Susumu Higuchi
Journal:  J Gastroenterol       Date:  2011-07-13       Impact factor: 7.527

8.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

9.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Etsuko Hashimoto; Satoru Yatsuji; Maki Tobari; Makiko Taniai; Nobuyuki Torii; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

10.  Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.

Authors:  Srinevas K Reddy; Omar Hyder; J Wallis Marsh; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Luca Aldrighetti; David A Geller; Christine Sempoux; Vlad Herlea; Irinel Popescu; Robert Anders; Laura Rubbia-Brandt; Jean-Francois Gigot; Giles Mentha; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2013-01-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.